Alaunos Therapeutics Profit Margin

The latest profit margin for TCRT is -136966.67% as of March 2026. That compares with -40710.0% in the prior-year period — down 236.4% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Alaunos Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TCRT's profit margin moved from -40710.0% to -136966.67% — a 236.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Alaunos Therapeutics's valuation or profitability profile.

Against Healthcare companies, TCRT currently prints -136966.67% for profit margin, while the sector average sits near 14.34%. That is roughly 954918.8% below the sector mean. Large gaps often invite a closer look at Alaunos Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Alaunos Therapeutics converts resources into returns. At -136966.67%, TCRT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -40710.0% in the prior-year period — down 236.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TCRT's profit margin (-136966.67%), review year-over-year change from -40710.0%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.